1. Home
  2. ESYN vs MDXH Comparison

ESYN vs MDXH Comparison

Compare ESYN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ESYN

EnerSyn Global Inc. Common Stock

N/A

Current Price

$1.80

Market Cap

19.8M

Sector

Health Care

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

BUY

Current Price

$0.21

Market Cap

18.5M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
ESYN
MDXH
Founded
2021
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8M
18.5M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ESYN
MDXH
Price
$1.80
$0.21
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.13
AVG Volume (30 Days)
14.6K
★ 1.2M
Earning Date
10-22-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 47.37
N/A
EPS
N/A
★ N/A
Revenue
★ $866,926.00
N/A
Revenue This Year
N/A
$5.10
Revenue Next Year
N/A
$13.22
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.75
$0.17
52 Week High
$2.68
$5.33

Technical Indicators

Market Signals
Indicator
ESYN
MDXH
Relative Strength Index (RSI) 30.86 23.92
Support Level $1.82 N/A
Resistance Level $2.13 $0.66
Average True Range (ATR) 0.15 0.05
MACD -0.02 -0.05
Stochastic Oscillator 24.55 8.22

Price Performance

Historical Comparison
ESYN
MDXH

About ESYN EnerSyn Global Inc. Common Stock

EnerSyn Global Inc, formerly HWH International Inc and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore. The Company is presently developing Hapi Marketplace, a business-to-consumer platform featuring diverse product categories, and Hapi Wealth Builder, an educational program focused on wealth-building strategies.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: